Provided by Tiger Trade Technology Pte. Ltd.

Celldex Therapeutics

30.30
-1.4500-4.57%
Post-market: 30.300.00000.00%16:59 EDT
Volume:904.83K
Turnover:27.65M
Market Cap:2.01B
PE:-7.77
High:31.75
Open:31.29
Low:30.00
Close:31.75
52wk High:34.52
52wk Low:14.40
Shares:66.45M
Float Shares:53.21M
Volume Ratio:0.64
T/O Rate:1.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9000
EPS(LYR):-3.9000
ROE:-40.62%
ROA:-26.12%
PB:3.82
PE(LYR):-7.77

Loading ...

Should Celldex’s Global Phase 3 EMBARQ Trial for Barzolvolimab in Inducible Urticaria Require Action From CLDX Investors?

Simply Wall St.
·
Dec 11, 2025

BRIEF-Celldex Initiates Global Registrational Phase 3 Program Of Barzolvolimab In Cold Urticaria And Symptomatic Dermographism

Reuters
·
Dec 09, 2025

Celldex Therapeutics Inc - Data From Open Label Extension Expected in Q1 2026

THOMSON REUTERS
·
Dec 09, 2025

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

THOMSON REUTERS
·
Dec 09, 2025

Celldex SVP & General Counsel Freddy A. Jimenez Reports Sale of Common Shares

Reuters
·
Dec 09, 2025

How Investors May Respond To Celldex Therapeutics (CLDX) Leadership Change and Widening Third-Quarter Losses

Simply Wall St.
·
Nov 22, 2025

Celldex Therapeutics (CLDX): Assessing Valuation After Recent Revenue Growth and Share Price Swings

Simply Wall St.
·
Nov 19, 2025

Exozymes CEO Unveils Market-Ready Cell-Free Enzyme Technology

Reuters
·
Nov 19, 2025

Celldex Therapeutics Files Initial Beneficial Ownership Statement for SVP & Chief Commercial Officer Teri Lawver

Reuters
·
Nov 13, 2025

Celldex Therapeutics Is Maintained at Underweight by Barclays

Dow Jones
·
Nov 11, 2025

Stifel Nicolaus Sticks to Its Buy Rating for Celldex (CLDX)

TIPRANKS
·
Nov 11, 2025

Mizuho Securities Remains a Buy on Celldex (CLDX)

TIPRANKS
·
Nov 11, 2025

Barclays Sticks to Its Sell Rating for Celldex (CLDX)

TIPRANKS
·
Nov 11, 2025

Celldex Therapeutics Q3 EPS $(1.01) Misses $(0.91) Estimate

Benzinga
·
Nov 11, 2025

Top News Today/Canada: Barrick's Interim CEO Gets to Work

Dow Jones
·
Nov 11, 2025

Clinical-stage biotech Celldex's Q3 net loss widens to $67 mln

Reuters
·
Nov 11, 2025

Celldex Therapeutics reports third quarter net loss of $67.0 million on revenue of $0.0 million

Reuters
·
Nov 11, 2025

Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday?

Benzinga_recent_news
·
Nov 11, 2025

Celldex Therapeutics Appoints Teri Lawver as Chief Commercial Officer

Reuters
·
Nov 10, 2025

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

THOMSON REUTERS
·
Nov 10, 2025